Prellis Biologics, Inc. announced that it has generated 300 human IgG antibodies that bind to either the S1 or S2 spike protein of the SARS-CoV2-Wuhan strain of the novel coronavirus.

Bio-Rad has announced that its CFX96 Dx Real-Time PCR System has been listed with the FDA for IVD testing and may be used to help in the diagnosis of COVID-19.

Oxford Immunotec has released the T-SPOT® Discovery™ SARS-CoV-2 kit for research into measuring the T cell immune response to SARS-CoV-2, which may offer new insights into immunity to COVID-19.

LKF has expanded its existing range of COVID-19 testing methods for clinical trials.

Moderna, Inc. announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

The UK Government has announced £65.5 million of new funding for the vaccine being developed at the University of Oxford as coronavirus vaccine trials accelerate.

EUROIMMUN is offering a comprehensive panel of SARS-CoV-2 tests, validated for in vitro diagnostic purposes.

Porvair Sciences has reported how its Chromatrap® ChIP kits can provide a solution for antibodies suppliers looking to validate the performance of the antibodies they produce for chromatin immunoprecipitation assay kits.

DefiniGEN has identified iPSC-derived intestinal organoids that could be used to help structure in vitro studies of the biology of SARS-CoV2 infection across cohorts of multiple patients.

CEPI to provide up to an additional US$384 million funding for phase 1 and 2 clinical trials and large-scale manufacture of Novavax’ NVX-CoV2373 vaccine candidate, taking total investment in NVX-COV2373 to US $388 million.